SALMAN KHAN: I'' m here with Professor Laurence Baker from Stanford Medical School, and also I'' m wishing he can at the very least start to obtain me to comprehend something that I'' ve always questioned and also stressed about a little. Let'' s say that I ' m. some medication firm. So allow me create this down. So I ' m some pharma. business, pharma business A right over here,. and also let ' s claim that I invest 10 years and also$ 100.
million in some medication. I obtain it with all. of the clinical tests, and it gets accepted by the FDA
. And let ' s say, just for purpose of.
simplicity, it cures disease x. Now as soon as I reach.
that point, I ' m feeling quite great regarding. myself as a pharma company.What takes place next? I'' m assuming that I'' m going. to have to go to the insurance provider and also maybe.
Medicaid and also Medicare as well as identify just how much.
they'' re going to pay for it, yet exactly how does that.
conversation also happen? TEACHER LAURENCE BAKER: Yeah. So you'' re going
to. have a discussion with a number of various individuals. In the US, we have great deals of.
different private insurance plans. We'' ve got federal government plans. As well as you ' re really going. to have conversations with Europe and also with a few of the.
other systems all over the world, due to the fact that each system is going.
to make its very own decision. SALMAN KHAN: And they have.
a various method of doing it.PROFESSOR LAURENCE. BAKER: They might some have
resemblances in the. means that they probably want to speak to you about. SALMAN KHAN: Does there. often tend to be a lead system? Does it tend to be. either the Europeans, or does it have a tendency to be the. exclusive insurers in the United States? Or do you just begin all of. those conversations at the same time because
there ' s so much. cash on the table? PROFESSOR LAURENCE. BAKER: So there will certainly be some method
. your service is going to pertain to since
it ' s. really tough to have all of these conversations. specifically all at once. So you ' ll talk
to the US. You ' ll talk with Europe. And also'there are some. instances in which individuals have actually viewed the regulative. procedures in Europe as a little less complicated. for some points, so they might desire.
to begin in Europe.
But in various other instances, if.
you'' re taking a look at a medication that maybe several of the. nationwide systems in Europe are much less likely to.
intend to pay for, you might wish to begin.
with the US, where there'' s a little.
much more flexibility.SALMAN KHAN: However the.
basic policy of thumb is all the cash is in Europe.
as well as the US mainly today. PROFESSOR LAURENCE.
BAKER: A great deal of it. The Oriental systems, several of.
them are rather sophisticated as well as utilizing a lot of the.
sophisticated drugs, also, yet I assume the.
majority of the cash remains in the US and also.
Europe, The United States And Canada. SALMAN KHAN: As Well As between.
Europe and the United States, I think I'' ve constantly envisioned.
North America was perhaps where the bulk of the cash was.But is that the situation? TEACHER LAURENCE BAKER:. The US, well, our health treatment system invests even more than. everybody worldwide, as well as it '
s true for drugs, as well. We spend more on medicines right here. than many various other areas.
SALMAN KHAN: OK. So certainly if I ' m. right here, pharma'business A, I desire to see to it I. obtain this right in the United States
. PROFESSOR LAURENCE BAKER: Yeah. Eventually you most likely. care a whole lot concerning the US.
SALMAN KHAN: Part. of my financial investment that
I made is based on. some understanding that, if I got all the. means with, that I would get some sort of. return within the United States. Will I always
. quickly go to Medicare since they ' re one of. the biggest gamers, or will certainly I most likely to, like we.
talked about, Blue Cross Blue Shield or Kaiser or some. of these other players? TEACHER LAURENCE.
BAKER: So Medicare is in fact an interesting.
one for medication prices since, historically, Medicare
. has actually not been a huge coverer and also still isn ' t of a whole lot of. the medications that you hear about.So Medicare does.
not pay on its own for outpatient medicines
, drugs.
that you may take in your home.
SALMAN KHAN: Truly? I always presumed. that– they wear ' t. teacher LAURENCE. BAKER: So Medicare, in its major pieces– Medicare,. we call Part A, Component B, Component C– so Part An and also.
Component B, let'' s begin there. They tend not to cover, or they.
don'' t cover, outpatient medicines.
If you get a medication. in the'health center while you ' re hospitalized,. Medicare will pay for those.
Therefore if you ' ve. obtained a medicine that ' s going to be mainly.
made use of because setup, you ' re mosting likely to speak. to Medicare regarding it, and that ' s mosting likely to. be an essential piece of the conversation. However if you'' re talking
. regarding an outpatient medicine,
you ' re talking with.
lots of [INAUDIBLE] SALMAN KHAN: Currently,'when. we ' re claiming outpatient, inpatient is you ' re. in the medical facility. You ' re unwell. You need, I put on ' t recognize,. morphine right currently.
That ' s inpatient drug. TEACHER LAURENCE BAKER: Yeah. SALMAN KHAN: Outpatient is,. hello, you ' re going back residence. Take this three times a day. PROFESSOR LAURENCE BAKER: Yeah. Someone sends you. to the pharmacy to get the prescription,. and you take it home with you.
That ' s mosting likely to be an. outpatient kind of medication.
So Medicare doesn ' t cover that. in its almost all An and also Component B. There ' s Medicare Component D, which.
is a medicine plan in Medicare, and also that
will cover a whole lot. of the outpatient medicines. As well as so there you'' d have.
discussions with them. But'most of the.
Medicare Part D strategies are basically. private firms that Medicare contracts with.
So you ' re not actually speaking to. the government then. You ' re speaking to these.
personal strategies that have actually acquired with Medicare.
to supply Component D care.SALMAN KHAN: So as soon as. again going back to the core of the concern. of exactly how are these medications going to get paid for,. how are we going to identify the rate at. which these drugs earn money for, it goes straight back.
to the private strategies'once more due to the fact that they ' re.
mosting likely to agreement. Part D is mosting likely to state,. oh, you ' re Medicare Component D. We ' re mosting likely to.
go to most likely to Aetna. We ' re going to go to a few other. strategy or whoever it may be.
I wear ' t know who it could be. TEACHER LAURENCE.
BAKER: Whoever is supplying those Part D plans. SALMAN KHAN: Whoever is. supplying those Component D strategies– and so it will certainly ride off of. whatever that private party has already worked out with.
the pharma business. PROFESSOR LAURENCE BAKER: It. would certainly be relevant, most likely, to that.
SALMAN KHAN: OK. So allow ' s state that we have.
some kind of insurance.
I ' m lacking letters now.Let ' s call this insurance.
firm Y right over here.
And also I go have a discussion. with insurer Y, and I ' m like, hello,. this is a big offer.
Illness x, you know it ' s. been killing individuals.
I want$ 1 million per pill. PROFESSOR LAURENCE.
BAKER: Yeah, and so those have actually been actually interesting. conversations in the United States. So there ' s some.
bargaining to and fro between the insurance policy
. company and also the drugmaker.
The drugmaker is going to. have spent a great deal of money.You ' ve obtained $100
. million up there'. SALMAN KHAN: Yes. I are worthy of to make at least $10. billion off– I ' m only joking. TEACHER LAURENCE BAKER:. So there ' s a specific amount, to a particular level [FAINT] SALMAN KHAN: It '
s called. securing in a negotiation. PROFESSOR LAURENCE BAKER: Right. You begin with what.
you believe you can obtain. SALMAN KHAN: Yes. Absolutely, yeah. [PROFESSOR LAURENCE BAKER:. Press?] that number to get everyone
' s mind about, yeah. So in truth, it sets you back. more than$ 100 million to take a medication.
via the tests, to do the growth job.
So they ' re going to be sitting. there with a number, at least internally, claiming, we'want.
to obtain our$ 800 million, our$ 1.5 billion back from this.
And so we ' re mosting likely to try.
and also price it as necessary. SALMAN KHAN: Since. it ' s not simply the expense
of that. medicine– so what is the cost? Do you know
that off the top. of your head, the average medication? PROFESSOR LAURENCE BAKER:. It ' s numerous millions.So there ' s the.
growth prices that go in that the pharma. companies aren ' t usually going to chat a great deal about. As well as then there ' s. the expense
of getting with the tests as well as the FDA. authorizations, which people state$ 500 million and also up. They ' ll say higher
. numbers sometimes. SALMAN KHAN: For one given medicine? TEACHER LAURENCE BAKER: Yeah. SALMAN KHAN: $500 million. So it can be as high.
as $500 million. TEACHER LAURENCE.
BAKER: It can be higher.SALMAN KHAN: Can be.
better than$ 500 million. And also so that doesn ' t also take.'into the probability-weighted danger, that there'' s a. 10% opportunity that it fails or a 10% chance that it works. So it'' s truly, if'you
' re. spending $100 million per medicine and also just 1 out of.
10 of those medicines are going to obtain.
to the end area– TEACHER LAURENCE BAKER: Yeah. You'' ll see along the method. You won'' t spend a whole. heap and also'then discover. You ' ll learn symphonious.
So you ' ll have to invest. something to arrive. SALMAN KHAN: I see.
You ' ll stop. So although on one medicine, it.
could be $100 million or $500 million, they may have
invested. an additional$ 300 million or $400 million on medications that. didn ' t go anywhere.
PROFESSOR LAURENCE BAKER:. Plus their own growth costs behind-the-scenes. SALMAN KHAN: Plus their
. very own development costs. So if you attempt to totally fill.
the expense, it'' s a huge number. TEACHER LAURENCE.
BAKER: It'' s big, yeah. Right. Exactly. They'' re operating.
an operation where they'' ve reached place in a.
great deal of money in up front.When they get a. success, they need to
get sufficient out. of that success to pay for the operation,. to maintain things going with the following development round. So they ' re looking at. those kinds of numbers, and also they ' re attempting to number. out in this negotiation what they can market this for. As well as that ' s a back.
and also forth discussion. The insurance provider.
have some capacity to claim what they'' re. ready to pay, but a whole lot of these.
medicines, if they'' re doing the healing a disease that.
people care around, the pharma business have a great deal of.
capacity to come and say, this is what we need to obtain for.
this and established that price as well as be able to obtain.
it for a while.SALMAN KHAN: So undoubtedly,. the pharma company is coming below with. every one of this financial investment.
They definitely want. it to get covered. Yet the insurance policy firm,.
their motivation is they don'' t wish to look. like, every one of the unexpected, this business that doesn'' t. give the remedy for condition x. Do insurer.
ever before walk away and say, well,.
that'' s just way too much. I recognize you spent.
every one of this cash, but we just can'' t do that. That ' s just crazy.
PROFESSOR LAURENCE. BAKER: So it ' s a bit of a combined bag. The US doesn ' t. have a great deal of situations where insurance firms have. actually put their foot down and also claimed, no, they ' re. not going to do anything. They ' re not going. to have anything to do with some new.
drug that appears. And also a few of that ' s.
as a result of the presence of whole lots of different companies.So if
five of the firms. claim no but the following guy in line states yes, then the dynamic of.
that in an affordable market is commonly that everybody else.
will ultimately come around as well as claim, OK, we'' re. mosting likely to [INAUDIBLE] SALMAN KHAN: Someone is.
mosting likely to do something. They may not pay.
for it outright. The entire factor why we'' re. having this discussion is because there are some drugs.
that appear reasonably valued to me, yet there.
are some that resemble $30,000 a.
pill or something.I made up that
number. TEACHER LAURENCE BAKER: Yeah. So the situations, the.
really costly ones, are medicines that are.
unique– often tend to be special, a minimum of to some extent–.
treatment condition that obtains some high account, so.
people are stressed that they'' re mosting likely to pass away if they.
wear'' t obtain this drug. And also naturally, they'' re. still on patent.
That ' s an additional. feature of all this, where you obtain the high price. for a specific period of time until your patents run out. SALMAN KHAN: And Also.
then the common– PROFESSOR LAURENCE.
BAKER: And then common can be found in as well as the price– SALMAN KHAN: Can make them.
for the price of the tablet, which is– PROFESSOR LAURENCE BAKER:.
It drops considerably. SALMAN KHAN: Pennies or dollars. TEACHER LAURENCE.
BAKER: So exactly how you get these things established.
in a competitive market is an interesting inquiry. Among things that.
gets the trademark name drugs to be a little cheaper is.
competition within the class.So if there is two or 3. drug producers who
have something that will. essentially do the exact same thing
, that will certainly have a tendency to take the side. off the$ 30,000 a tablet kind of situation as well as obtain you down. to extra sensible costs.
It won ' t get you all the. method to common prices, yet [INAUDIBLE] SALMAN KHAN: It. just appears to me– you
simply discussed that very. couple of insurance provider have ever before ignored this. If you ever have a negotiation–. acquiring a used car– where among the two. parties is not leaving
, after that it doesn ' t appear. like there ' s in fact a hard, major negotiation. Am I obtaining that wrong? TEACHER LAURENCE.
BAKER: Yeah, I wear'' t know all the ins and also. outs of all these arrangements. There'' s lots that goes.
on in these points. But I believe that a person of the.
things that people would certainly claim concerning the US is that when.
a medication manufacturer thinks of relatively special,.
on-patent drug that does some tangible good,.
that they basically can set the price that they.
want to get for it.And they'' re going to make some
. calculation, since they might set a high enough rate that.
everyone would certainly state forget it. So they'' re mosting likely to try. and determine something. Yet they'' re trying
to. obtain as long as they can, and they obtain some
freedom for. a minimum of an amount of time to call that cost. SALMAN KHAN: So.
they'' ll get leeway, and also I presume there'' s some. variety of reasonableness where it'' s like,'OK. Yes, you ' ve done something.
fantastic for humanity. You'' re going to obtain a 35%.
return on your investment, however that shouldn'' t be a 300 %. return on your investment. PROFESSOR LAURENCE BAKER: Yeah. I wear ' t recognize at what point. the US would ever before stroll or the private insurance companies.
will ever before stroll from this. I sanctuary'' t seen it. truly occur, and also I think medicine companies are quite.
sophisticated regarding trying to figure out what.
rate they think they can make work as well as obtain that.
as high as they can obtain that. SALMAN KHAN: So.
I guess I'' m still vague to see that'' s making.
out below really well.PROFESSOR LAURENCE.
BAKER: This has actually been a truly. intriguing dispute.
Pharma companies put. substantial amounts of cash right into these medicines. And also occasionally, they do. some truly helpful points, as well as they obtain high costs. There are other individuals. who say that several of the important things that they ' re. getting high costs for aren ' t really useful. sufficient'or in some way we ' ve
been told we'require a. medicine that, if we had it to our own devices, we. would certainly never have actually come up with the truth that we need it. And also so what ' s the genuine.
value at the end of the day? And also I believe that'' s one. of the disputes we ' re going
to have in this. country momentarily.
The sector has actually been. thinking of brand-new things, as well as they ' re mosting likely to.
keep trying to do that. We intend to, from a social.
viewpoint, from a policy viewpoint, try to make.
sure that things we'' re doing are really important to culture.
and also not copies of other medicines or not creating a disease.
that didn'' t require an option and afterwards fixing the problem.And sometimes we.
stress that maybe we ' re getting some of'that. And I think that ' s the obstacle. for the US health insurance system, for the. governing procedures to attempt to guide the.
technology and guide the acquiring of these.
things to actually create one of the most value for society. It'' s been a difficulty.'It ' s mosting likely to be a difficulty. We have the obstacle, due to the fact that.
we have incredible chance with brand-new medications produced. SALMAN KHAN: So your gut.
sense is there probably are some medicines around that.
they'' re doing really well, well over as well as past.
the investment expense, but it'' s hard to'say.
It ' s really on a. situation by case basis. PROFESSOR LAURENCE. BAKER: Yeah, I put on ' t think you
' d intend to make. a common declaration regarding all the medications that have.
been uncovered. Several of the important things that.
we'' ve produced there in the last couple.
of decades are really vital medicines that are.
going to do a whole lot of good.And I assume there are disputes. about a few other ones where perhaps someone ' s been able. to be brilliant concerning marketing and offer it, and also we'' re less. sure that it ' s [FAINT] SALMAN KHAN: And that,.
in fact, marketing– I wear'' t intend to make this. discussion as well long– but some people raise that.
the medicine firms, they claim, look, there'' s a great deal. of financial investment right over here on this. Therefore they have to obtain some.
reasonable return on it, and that seems to make good sense,.
especially when you possibility weight it and also all of that.But they invest
a considerable.
amount of marketing also, on real advertising. You watch the nightly.
information, the majority of the ads, you'' re going
to. see a drug business. They do the medical professional suppers,.
and also they do all of their things like that. That seems to undermine that.
debate that every one of the cash is going with R&D. PROFESSOR LAURENCE BAKER: Right. If you just amounted to.
up the bucks, I'' m not exactly sure what the.
numbers would certainly come out like, and truthfully, the.
pharma companies aren'' t actually delighted. about informing everyone every one of the details of their.
companies completely factor. So definitely,.
there'' s a significant amount of marketing [FAINT] SALMAN KHAN: You invest a load.
of money on the advertising and marketing. And afterwards you obtain.
the customer here to place the pressure.
on the insurer as well as the medical professionals to.
say, hey, you much better cover that, or I'' m asking for that. PROFESSOR LAURENCE BAKER: Yeah. There was a time.
within my memory where we weren'' t allowed. to do direct to customer advertising and marketing, where the.
laws prohibited that.And the change
occurred,.
as well as now we'' re enabled to do it. And also it'' s actually altered the.
means that medications are marketed. SALMAN KHAN: And Also I.
have actually discovered that unusual because, if these are.
medications that are indicated to be by prescription, which.
ways that it ought to be a doctor'' s judgment.
on whether you must get the medicines,.
why is it being marketed on the every night news.
to a basic target market? TEACHER LAURENCE.
BAKER: Right– a basic audience who doesn'' t. comprehend all the ins as well as outs of the medication and whose.
doctor might or might not intend to put in the time to.
describe it all to them. SALMAN KHAN: Exactly. However after that they'' ll most likely to. the medical professional as well as state, please give me this drug. And afterwards the medical professional, it'' s easier. for them to say, well, sure.Why not? PROFESSOR LAURENCE BAKER: Yeah. No, I assume a great deal. of doctors would express a specific quantity. of aggravation concerning that
. Their individuals can be found in. It ' s difficult to have'the.
discussion in a brief time period, so it'' s simpler.
simply to provide the drug. SALMAN KHAN: Interesting.
